If you are not happy with the results below please do another search
Avacta Group, a clinical stage biopharmaceutical company developing cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has made new appointments to its Scientific Advisory Board (SAB),reflecting the progress ofthe Therapeutics Division and Avacta’s transition to a clinical stage company.
Agilent Technologies has signed a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions.
Porvair Sciences has installed new automated precision die-cutting equipmentthat has enabled a five-fold increase in its production capacity for porous plastic components. This major investment by the company is in response to a significant rise in demand from customers for precision components made from its high performance Vyon porous plastics.
San Diego, California-based Insightful Science, the software company enabling the Cloud for Scientific Discovery, has acquired De Novo Software,the maker of FCS Express. FCS Express is one of the fastest-growing flow cytometry data analysis solutions in the industry.
Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes.
Merck announced the winners of this year’s Future Insight Prize. The €1 million prize in the category of “Food Generation” was awarded during the Future Insight Days in Darmstadt, Germany, to Ting Lu, Professor of Bioengineering at the University of Illinois Urbana-Champaign, USA, and Stephen Techtmann, Associate Professor of Biological Sciences at Michigan Technological University, […]
Every day, regulatory, clinical, quality, and marketing teams at diagnostics manufacturers must refer to the EU’s upcoming In Vitro Diagnostic Regulation (IVDR).
Researchers at Chalmers University of Technology, Sweden, have succeeded in developing a method to label mRNA molecules, and thereby follow, in real time, their path through cells, using a microscope – without affecting their properties or subsequent activity. The breakthrough could be of great importance in facilitating the development of new RNA-based medicines.
CLSI publishes new document C64 – Quantitative Measurement of Proteins and Peptides by Mass Spectrometry, 1st edition
The Oxford, UK-based Orbit Discovery, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has raised US$7.6 million in funding.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
